They were not believed to be false positive

results as they were known mutations, the results were reproducible and adequate controls were analysed in parallel. There were 12 mutations detected by sequencing that were not detected by ARMS because the ARMS assays used were not designed to detect these mutations, either because the mutations were rare (melanoma study) or ARMS assays had not yet been developed to detect these mutations. However, using the larger panel of ARMS assays now available the number of mutations detected by ARMS would be significantly increased with potentially only 1 mutation being missed from this study. Even though ARMS is the more sensitive technique, in the NSCLC Vadimezan research buy samples from which DNA sequence could be obtained no mutations were detected by ARMS that were not detected by sequencing. Mutations AZD5582 were only missed by DNA sequencing due to assay fails owing to the low amounts of poor quality, fragmented DNA yielded from the samples. This probably reflected the fact that these samples had been macro-dissected prior to analysis, enriching for tumour and

increasing the abundance of mutant DNA in the sample. However, the macro-dissection process was very time-consuming and labour-intensive and required specialist pathologist input. Reducing the size of the PCR amplicons used in sequencing may also have reduced the number of samples that failed in DNA sequencing. In the melanoma study, no macro-dissection selleck inhibitor was performed. This was because the planned primary analysis method was ARMS and macro-dissection was thought unnecessary due to the sensitivity of the method. The results of the melanoma analysis reflected this as not all mutations detected by ARMS were visible on sequencing traces. They were not believed to be false positive results as they were known mutations, the results were reproducible and high levels of normal DNA was used as a control for non-specificity. As the analysis method for the melanoma study was ARMS we did not quantify the DNA prior to analysis because the ARMS assays contained

a control reaction that could be used to semi-quantify the DNA at the same time as performing the diagnostic reaction. Eliminating the quantification step reduced the Thiamet G analysis time. For the NSCLC study, however, the primary method was sequencing as there were only two EGFR mutant ARMS assays available at the time of the study and while the common mutations were well established, the number of rarer mutations being discovered was still increasing. To reduce the effort of sequencing in the many samples (179 samples were >10 copies/μl [empirically determined cut-off for sequencing]) that would have failed in 90% of the cases and to reduce the costs of the commercial assays we quantified the extracted DNA and only analysed the samples where there was a good chance of success.